Duality Biotherapeutics Sets March Board Meeting on 2025 Results and Dividend

Duality Biotherapeutics, Inc. ( (HK:9606) ) has issued an announcement.

Duality Biotherapeutics, Inc. is a Hong Kong-listed biopharmaceutical company focused on developing innovative therapeutic products. The company operates through its subsidiaries and is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard corporate governance structure for a listed biotech firm.

In line with its obligations as a public company, Duality Biotherapeutics has scheduled a board meeting for March 23, 2026 to review and approve its audited annual results for the year ended December 31, 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.

The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.

More about Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc. is a Hong Kong-listed biopharmaceutical company focused on developing innovative therapeutic products. The company operates through its subsidiaries and is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard corporate governance structure for a listed biotech firm.

In line with its obligations as a public company, Duality Biotherapeutics has scheduled a board meeting for March 23, 2026 to review and approve its audited annual results for the year ended December 31, 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.

Average Trading Volume: 713,944

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$29.15B

See more insights into 9606 stock on TipRanks’ Stock Analysis page.